• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by UroGen Pharma Ltd.

    5/15/26 1:46:26 PM ET
    $URGN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $URGN alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    UroGen Pharma Ltd.

    (Name of Issuer)


    Ordinary Shares, par value NIS 0.01 per share

    (Title of Class of Securities)




    M96088105

    (CUSIP Number)
    03/31/2026

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)




    schemaVersion:


    SCHEDULE 13G

    CUSIP Number(s):
    M96088105


    1Names of Reporting Persons

    The Toronto-Dominion Bank
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CANADA (FEDERAL LEVEL)
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    2,616,714.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    2,616,714.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,616,714.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.4 %
    12Type of Reporting Person (See Instructions)

    FI


    SCHEDULE 13G

    CUSIP Number(s):
    M96088105


    1Names of Reporting Persons

    TD SECURITIES INC.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    ONTARIO, CANADA
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    1,306.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    1,306.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,306.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0 %
    12Type of Reporting Person (See Instructions)

    FI


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    UroGen Pharma Ltd.
    (b)Address of issuer's principal executive offices:

    9 HA'TA'ASIYA ST, RA'ANANA, ISRAEL 4365007
    Item 2. 
    (a)Name of person filing:

    The Toronto-Dominion Bank TD SECURITIES INC.
    (b)Address or principal business office or, if none, residence:

    The principal office address of The Toronto-Dominion Bank ("TD Bank"): 66 Wellington Street West 12th Floor TD Tower Toronto, Ontario, Canada M5K 1A2 The principal office address of TD Securities Inc. ("TDSI"): 55 King Street West TD Tower 12th Floor Toronto, Ontario, Canada M5K 1A2
    (c)Citizenship:

    The Toronto-Dominion Bank - CANADA (FEDERAL LEVEL) TD SECURITIES INC. - ONTARIO, CANADA
    (d)Title of class of securities:

    Ordinary Shares, par value NIS 0.01 per share
    (e)CUSIP Number(s):

    M96088105
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    TD Bank - Bank TDSI - Broker Dealer
    Item 4.Ownership
    (a)Amount beneficially owned:

    2,618,020 TD Bank has the sole power to vote or direct the vote and the sole power to dispose or direct the disposition of 2,616,714 of these shares and TDSI has the sole power to vote or direct the vote and the sole power to dispose or direct the disposition of 1,306 of these shares. This schedule is jointly filed by TD Bank and TDSI. TD Bank is the sole owner of TDSI. TD Bank may be deemed to hold an indirect interest in the shares reported herein by TDSI by virtue of its ownership of TDSI. TD Bank disclaims ownership of the shares reported herein by TDSI except to the extent of its pecuniary interest therein. Each reporting person declares that neither the filing of this statement nor anything herein shall be construed as an admission that such person is, for the purposes of Section 13(d) of the US Securities Exchange Act of 1934 or any other purpose, (i) acting (or has agreed or is agreeing to act together with any other person) as a partnership, limited partnership, syndicate or other group for the purpose of acquiring, holding or disposing of securities of the Issuer or otherwise with respect to the Issuer or any securities of the Issuer or (ii) a member of any group with respect to the Issuer or any securities of the Issuer.
    (b)Percent of class:

    5.4  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    The Toronto-Dominion Bank - 2,616,714 TD SECURITIES INC. - 1,306

     (ii) Shared power to vote or to direct the vote:

    The Toronto-Dominion Bank - 0 TD SECURITIES INC. - 0

     (iii) Sole power to dispose or to direct the disposition of:

    The Toronto-Dominion Bank - 2,616,714 TD SECURITIES INC. - 1,306

     (iv) Shared power to dispose or to direct the disposition of:

    The Toronto-Dominion Bank - 0 TD SECURITIES INC. - 0

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Not Applicable
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    The Toronto-Dominion Bank
     
    Signature:Christina Petrou
    Name/Title:Christina Petrou / Executive Vice President & Chief Operating Officer
    Date:05/15/2026
     
    TD SECURITIES INC.
     
    Signature:Greg Nowakowski
    Name/Title:Greg Nowakowski / Chief Compliance Officer
    Date:05/15/2026
    Exhibit Information

    Exhibit I JOINT FILING AGREEMENT This will confirm the agreement by and among the undersigned that the Schedule 13G filed with the Securities and Exchange Commission on or about the date hereof with respect to the beneficial ownership by the undersigned of the ordinary shares of UroGen Pharma Ltd. will be filed on behalf of each of the persons and entities named below in accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Dated: May 15, 2026 THE TORONTO-DOMINION BANK By: /s/ Christina Petrou Title: Executive Vice President & Chief Operating Officer TD SECURITIES INC. By: /s/ Greg Nowakowski Title: Chief Compliance Officer

    Get the next $URGN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $URGN

    DatePrice TargetRatingAnalyst
    5/11/2026$43.00Buy
    Ladenburg Thalmann
    4/10/2026$40.00Buy
    Jefferies
    8/19/2025$36.00Overweight
    Piper Sandler
    6/16/2025$50.00Neutral → Buy
    H.C. Wainwright
    5/22/2025Buy → Neutral
    H.C. Wainwright
    4/16/2025$23.00Sector Outperform
    Scotiabank
    2/19/2025$31.00Buy
    Ladenburg Thalmann
    8/22/2024$40.00Buy
    Guggenheim
    More analyst ratings

    $URGN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Robinson James A. Jr. converted options into 2,000 units of ordinary shares, increasing direct ownership by 50% to 6,000 units (SEC Form 4)

    4 - UroGen Pharma Ltd. (0001668243) (Issuer)

    5/27/26 8:04:51 AM ET
    $URGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Schoenberg Mark sold $300,000 worth of Ordinary Shares (10,000 units at $30.00) as part of a pre-agreed trading plan, decreasing direct ownership by 7% to 134,985 units (SEC Form 4)

    4 - UroGen Pharma Ltd. (0001668243) (Issuer)

    5/11/26 3:54:04 PM ET
    $URGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Robinson James A. Jr. converted options into 2,000 units of ordinary shares, increasing direct ownership by 100% to 4,000 units (SEC Form 4)

    4 - UroGen Pharma Ltd. (0001668243) (Issuer)

    2/27/26 4:44:12 PM ET
    $URGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $URGN
    SEC Filings

    View All

    UroGen Pharma Ltd. filed SEC Form 8-K: Other Events

    8-K - UroGen Pharma Ltd. (0001668243) (Filer)

    6/2/26 8:04:53 AM ET
    $URGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by UroGen Pharma Ltd.

    SCHEDULE 13G - UroGen Pharma Ltd. (0001668243) (Subject)

    5/15/26 1:46:26 PM ET
    $URGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by UroGen Pharma Ltd.

    10-Q - UroGen Pharma Ltd. (0001668243) (Filer)

    5/6/26 8:05:18 AM ET
    $URGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $URGN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Ladenburg Thalmann resumed coverage on UroGen Pharma with a new price target

    Ladenburg Thalmann resumed coverage of UroGen Pharma with a rating of Buy and set a new price target of $43.00

    5/11/26 8:14:06 AM ET
    $URGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jefferies initiated coverage on UroGen Pharma with a new price target

    Jefferies initiated coverage of UroGen Pharma with a rating of Buy and set a new price target of $40.00

    4/10/26 8:36:03 AM ET
    $URGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Piper Sandler initiated coverage on UroGen Pharma with a new price target

    Piper Sandler initiated coverage of UroGen Pharma with a rating of Overweight and set a new price target of $36.00

    8/19/25 8:36:26 AM ET
    $URGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $URGN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    UroGen Announces Agreement Resolving Patent Litigation Relating to JELMYTO® (mitomycin) for pyelocalyceal solution

    Agreement reinforces the value of UroGen's innovation and reflects the strength of the Company's intellectual property portfolioTeva will be granted a non-exclusive license to sell its generic version of JELMYTO beginning on September 15, 2030, if approved by the FDA PRINCETON, N.J., June 02, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a biotechnology company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it has entered into a settlement and license agreement (the "Agreement"') with Teva Pharmaceuticals, Inc. and Teva Pharmaceuticals, USA, Inc. (collectively, "Teva"). This Agreement resolve

    6/2/26 8:00:00 AM ET
    $URGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    UroGen Pharma to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

    PRINCETON, N.J., June 01, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a biotechnology company focused on transforming the treatment of urothelial and specialty cancers, today announced that management will present at the Goldman Sachs 47th Annual Global Healthcare Conference to take place on June 8-10, 2026. Goldman Sachs 47th Annual Global Healthcare Conference Date / Time:June 10, 2026, at 8:40 AM ETFormat:Fireside chat and 1x1 investor meetingsLocation:Miami Beach, FLWebcast Link:here The webcast from the conference will also be available on UroGen's corporate website, under Events & Presentations. A replay will be available for approximately 90 days. About UroGen Pharm

    6/1/26 4:10:00 PM ET
    $URGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    UroGen Reports 94.5% Six-Month Duration of Response in Phase 3 UTOPIA Trial, Advancing UGN-103 Toward Potential Approval in Recurrent Low-Grade Intermediate-Risk NMIBC

    PRINCETON, N.J., May 15, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a biotechnology company focused on transforming the treatment of urothelial and specialty cancers, today announced UGN-103 achieved a 94.5% (95% CI: 86.1, 97.9) durability of response (DOR) at six months by Kaplan-Meier estimate, in the ongoing Phase 3 UTOPIA trial of UGN-103 (mitomycin) for intravesical solution in patients with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). The six-month results from UTOPIA are generally consistent with the 91.9% (95% CI: 86.9, 95.0) six-month DOR observed with ZUSDURI™ (mitomycin) for intravesical therapy in its pivotal ENVISION t

    5/15/26 8:00:00 AM ET
    $URGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $URGN
    Leadership Updates

    Live Leadership Updates

    View All

    UroGen Appoints Chris Degnan as Chief Financial Officer

    Mr. Degnan has extensive experience in financial strategy, investor relations, SEC reporting, accounting and compliance UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that Chris Degnan has been appointed Chief Financial Officer. Mr. Degnan succeeds Don Kim, who is leaving UroGen to pursue other opportunities. "Under Don's financial stewardship, we have strengthened our financial position and achieved significant milestones, which include multiple capital raises and investing in the potential commercial launch of UGN-102 for low-grade intermediate-risk non-musc

    10/9/24 8:00:00 AM ET
    $URGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    UroGen Pharma Appoints David Lin as New Chief Commercial Officer

    UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today announced that David Lin will join UroGen as its Chief Commercial Officer and member of the Executive Leadership Team. In this role, David will be spearheading UroGen's commercial strategy, including preparation for the potential launch of our lead pipeline candidate UGN-102, if approved, and driving the continued growth and commercialization of JELMYTO® (mitomycin) for pyelocalyceal solution. David Lin brings to UroGen a wealth of experience garnered from a distinguished career in the pharmaceutical industry. Prior to joining U

    6/3/24 8:00:00 AM ET
    $URGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NorthStar Appoints Peter Pfreundschuh to Board of Managers

    NorthStar Medical Technologies, LLC, parent company of NorthStar Medical Radioisotopes, LLC, a global innovator in development, production and commercialization of radiopharmaceuticals used to detect and treat cancer and other serious diseases, today announced the appointment of Peter (Pete) Pfreundschuh to its Board of Managers, effective April 1, 2024. Following this appointment, the Board will comprise of 9 directors, 6 of whom are non-executive. "We are pleased to welcome Pete to the NorthStar Board," said Stephen Merrick, Executive Chairman of NorthStar. "Pete has deep experience in the pharmaceutical and biotechnology industry, with extensive knowledge in corporate finance, business

    4/15/24 9:00:00 AM ET
    $FREQ
    $URGN
    $VYGR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Biotechnology: In Vitro & In Vivo Diagnostic Substances

    $URGN
    Financials

    Live finance-specific insights

    View All

    UroGen Reports ZUSDURI™ Revenue More Than Doubled Quarter-over-Quarter and Provides First Quarter 2026 Financial Results and Highlights

    ZUSDURI™ generated revenue of $29.2 million in Q1 2026, representing 109% quarter-over-quarter growth, reflecting broader utilization with the permanent J Code effective January 1, 2026JELMYTO achieved $21.7 million in revenue in Q1 2026, representing year-over-year growth of 7%Continued advancement of next-generation pipeline, UGN-103 on track for NDA submission in the second half of 2026; six-month durability data expected in mid-2026UroGen to host Key Opinion Leader (KOL) panel highlighting real-world experience with ZUSDURI at the American Urological Association (AUA) annual meeting on May 17th at 8:30 AM ETConference call and webcast to be held today at 10:00 AM ET PRINCETON, N.J., May

    5/6/26 8:00:00 AM ET
    $URGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    UroGen Pharma to Report First Quarter 2026 Financial Results on Wednesday, May 6th, 2026

    PRINCETON, N.J., April 29, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will report first quarter 2026 financial results on Wednesday, May 6th, 2026, prior to the open of the stock market. The announcement will be followed by a live audio webcast and conference call at 10:00 AM Eastern Time. A live public webcast of the earnings conference call can be accessed on UroGen's Investor Relations website. Following the live webcast, a replay will be available on the site for approximately 30 days. About UroGen Pharma Ltd. UroGen

    4/29/26 8:00:00 AM ET
    $URGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    UroGen Announces ZUSDURI™ Launch is On-Track and Reports Fourth Quarter and Full Year 2025 Financial Results

    Commercial launch is on-track for ZUSDURI™, the first and only FDA-approved medication for adults with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC); net sales in 2025 were $15.8 million, reflecting the initial launch period ahead of the permanent J CodePermanent J Code for ZUSDURI became effective on January 1, 2026, streamlining reimbursement procedures and supporting broader patient accessJELMYTO® achieved net product sales of $94 million in 2025, representing year-over-year underlying demand sales growth of 7%Announced refinancing of existing term loan with Pharmakon Advisors that provides additional non-dilutive capital at more favorable termsCon

    3/2/26 8:00:00 AM ET
    $URGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $URGN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by UroGen Pharma Ltd.

    SC 13D/A - UroGen Pharma Ltd. (0001668243) (Subject)

    11/18/24 6:16:04 AM ET
    $URGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by UroGen Pharma Ltd.

    SC 13G/A - UroGen Pharma Ltd. (0001668243) (Subject)

    11/14/24 7:46:37 PM ET
    $URGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by UroGen Pharma Ltd.

    SC 13G/A - UroGen Pharma Ltd. (0001668243) (Subject)

    11/14/24 5:46:12 PM ET
    $URGN
    Biotechnology: Pharmaceutical Preparations
    Health Care